Browse the evidence

GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations, offering a secondary benefit for OSA patients who have high cardiometabolic risk.

For OSA patients with diabetes or high heart disease risk, GLP-1 agonists provide dual benefits: improving sleep apnea and reducing long-term cardiovascular mortality.

Resmetirom (Rezdiffra), a thyroid hormone receptor-beta (THR-β) agonist, is the first FDA-approved pharmacotherapy for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3), demonstrating significant resolution of MASH and improvement in liver fibrosis compared to placebo.

If you have non-cirrhotic MASH with moderate to advanced fibrosis, ask your doctor about Resmetirom (Rezdiffra). It is the first FDA-approved drug for this condition, taken orally alongside diet and exercise, and has been shown to significantly improve liver health compared to placebo.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (7-14 mg) significantly improve glycemic control (HbA1c reduction) in patients with type 2 diabetes compared to placebo and various active control drugs.

For individuals with type 2 diabetes, semaglutide (available as a once-weekly injection or daily oral tablet) is highly effective at lowering blood sugar levels (HbA1c) compared to many other treatments, including insulin and other common diabetes medications. It offers a significant advantage in achieving target HbA1c levels (<7%) for a large proportion of patients. The risk of hypoglycemia is relatively low, and the once-weekly dosing can help improve compliance.

Individuals with Type 2 Diabetes (T2D) exhibit significantly reduced cardiorespiratory fitness (CRF), measured as peak oxygen uptake (VO2peak), compared to healthy controls, with reductions averaging 13.9% for absolute VO2peak and 17.4% for relative VO2peak.

If you have Type 2 Diabetes, expect your maximum oxygen uptake to be lower than a healthy peer's, even if you feel fine. This is a physiological marker of the disease, not a lack of effort. Start exercise interventions at a lower intensity to manage early fatigue, and focus on consistency rather than high intensity initially, as improving this baseline fitness is critical for long-term health outcomes.

Among patients with type 2 diabetes in placebo-controlled trials, baseline BMI has significantly increased over time (rising by ~0.70 kg/m² per decade), indicating a growing prevalence of obesity and inadequate management of weight despite improved glycemic control.

If you have Type 2 Diabetes, your weight is likely increasing even if your blood sugar is controlled. This meta-analysis of over 260,000 patients shows that baseline BMI has risen by 0.7 kg/m² every decade. You cannot ignore weight management; it is becoming harder, not easier, to maintain a healthy weight with current standard care. Focus on energy balance (diet and activity) as rigorously as you focus on glucose numbers.

Baseline HbA1c levels in Type 2 Diabetes patients have significantly declined over time (from ~10.6% to ~7.9%), reflecting improved glycemic control in clinical trial populations.

Blood sugar control in Type 2 Diabetes has improved significantly over the last 35 years, with average baseline HbA1c dropping from 10.6% to 7.9%. This suggests that modern detection and management strategies are more effective. However, this improvement in glucose control has not prevented the rise in obesity, meaning you must address both metrics.

GLP-1 receptor agonists (GLP-1RA) are effective pharmacological interventions for obesity that work by binding to GLP-1 receptors to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite.

GLP-1 receptor agonists are a key pharmacological tool for treating obesity. They work by mimicking a gut hormone to reduce appetite and improve metabolic function. Consult a doctor to see if this treatment is appropriate for you.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) provide robust cardiorenal protection in type 2 diabetes, reducing cardiovascular mortality, heart failure hospitalizations, and kidney disease progression independent of glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, standard sugar-lowering drugs may not be enough. Newer classes of drugs (SGLT2 inhibitors like Jardiance/Farxiga and GLP-1 agonists like Ozempic/Victoza) are proven to significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. These benefits occur even if your blood sugar numbers don't change drastically, so discuss these specific organ-protective benefits with your doctor.

Higher BMI, particularly severe obesity (Class 2 and 3), is robustly associated with increased risk of heart failure and atrial fibrillation, independent of traditional risk factors.

Maintaining a healthy weight is critical for preventing heart failure and irregular heartbeats. Severe obesity significantly increases these risks, even if your blood pressure and cholesterol are managed. Weight management should be treated as a primary medical intervention to protect heart health.

Females with severe obesity face a disproportionately higher relative risk for stroke, total CVD, and all-cause mortality compared to males with similar obesity levels.

Women with obesity should be particularly vigilant about stroke risk, as their relative risk increases more sharply with obesity severity than men's. Regular cardiovascular screening is essential for women with higher BMI.

Metformin therapy reduces the incidence of new-onset type 2 diabetes in high-risk adults (BMI ≥35, age 25-59, fasting glucose ≥110 mg/dL, or prior gestational diabetes) and provides long-term cardiovascular and microvascular benefits.

If you are at high risk for type 2 diabetes (overweight, older than 25, or have a history of gestational diabetes), metformin can help prevent the disease. It is cost-effective and provides long-term benefits even after stopping the drug. Discuss with your doctor if you are a candidate, especially if lifestyle changes alone are insufficient.

Ketogenic diets (≤10% carbs) produce greater weight loss but also greater increases in LDL and total cholesterol compared to moderate-carb diets (26-45% carbs).

If you choose a strict ketogenic diet (under 10% carbs), expect greater weight loss but also a significant rise in LDL and total cholesterol. If you want a balance of weight loss and heart health markers, a moderate-carb diet (26-45% carbs) might be a better choice.

Higher BMI categories, particularly Class III obesity (BMI ≥40 kg/m2), are strongly associated with worse self-reported overall health, quality of life, severe pain, fatigue, and limited physical activity, as well as an increased risk of developing chronic pain syndrome, chronic fatigue syndrome, fibromyalgia, and insomnia.

If you have obesity, do not ignore persistent pain, fatigue, or sleep issues. These are not just 'side effects' of weight but significant health risks linked to conditions like fibromyalgia and chronic fatigue. Seek medical evaluation for these symptoms, as treating them can improve your quality of life and functional ability, independent of weight loss goals.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.

If you have type 2 diabetes and existing heart disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications, taken as a weekly injection, have been proven to significantly lower your risk of heart attacks, strokes, and death compared to standard treatments. This is a critical step for protecting your heart and kidneys.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about weekly semaglutide injections. This treatment has been shown to significantly slow the progression of kidney disease and reduce the risk of heart-related death and overall death, offering strong protection for your kidneys and heart.

Semaglutide reduces the incidence of major cardiovascular adverse events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in patients with pre-existing cardiovascular disease and overweight/obesity, regardless of diabetes status.

If you have existing heart disease and are overweight, semaglutide may significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit exists even if you do not have diabetes.

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with cardio-renal-metabolic syndrome, regardless of diabetes status.

If you have heart failure, chronic kidney disease, or type 2 diabetes with high cardiovascular risk, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys, not just your blood sugar, and work even if you don't have diabetes. The benefits are substantial and supported by major clinical trials.

Mechanical tension is the primary and sufficient stimulus for load-induced human skeletal muscle hypertrophy, whereas acute hormonal spikes, metabolic stress, and cell swelling ('the pump') do not meaningfully contribute to the hypertrophic process.

To build muscle, prioritize mechanical tension through resistance training (lifting weights with progressive overload). Do not design your workouts around chasing a 'pump' or relying on metabolic stress (high reps, short rest) as primary drivers, as these do not add to hypertrophy beyond what mechanical tension provides. Similarly, do not expect natural acute hormonal spikes to drive growth; they are not required for hypertrophy to occur.

Healthcare professionals (HCPs) significantly overestimate patient fear of injectable weight loss medications, leading to under-prescription of these effective treatments.

Doctors often assume patients hate needles, but many don't. If you are open to injections, tell your doctor. They may not be offering them because they think you'll refuse, not because you actually will.

Patients prioritize minimizing gastrointestinal side effects (nausea, diarrhea) over maximum percentage of body weight loss, whereas HCPs prioritize maximum weight loss.

When choosing a weight loss medication, patients care more about avoiding stomach issues than getting the absolute lowest number on the scale, while doctors care more about the scale number. Discuss your tolerance for side effects with your doctor to find the right balance.

Childhood obesity is a strong predictor of adult obesity, with obese children being approximately five times more likely to remain obese in adulthood compared to normal-weight peers.

If your child is obese, do not wait for them to 'grow out of it.' The risk of them remaining obese into adulthood is 80%. Address dietary habits and physical activity early to prevent long-term metabolic health issues.

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Metabolic bariatric surgery is the most effective treatment for obesity across all BMI classes, offering durable weight loss and improvement in comorbidities.

For eligible patients (BMI ≥35, or 30-34.9 with failed lifestyle/pharma), metabolic bariatric surgery (sleeve or bypass) is the most effective treatment for durable weight loss and comorbidity improvement. It is recommended for BMI ≥35 regardless of comorbidities.

High-efficacy anti-obesity medications (AOMs) like semaglutide and tirzepatide produce significant weight loss in the majority of patients, but a subset of non-responders exists, and predictors of response or intolerance are currently unknown.

High-efficacy AOMs like semaglutide and tirzepatide work for most people, but not all. If you are a non-responder, it is not your fault, and current science cannot yet predict who will respond. Discuss alternative strategies or phenotypes with your provider.